The landmark study from Tata Memorial Centre (TMC) and the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), both premier institutions in oncology research and education in India, has spotlighted a stark reality: newer cancer treatments, particularly immunotherapies and targeted therapies, remain prohibitively expensive for the vast majority of Indians. Published in the journal Head & Neck in early 2026, the research titled “Disparity in the Markers of Affordability Across Targeted- and Immune-Therapy Drugs Used in Head and Neck Cancers” analyzes pricing across seven countries, revealing a global affordability chasm, but one especially acute in low- and middle-income nations like India.
Head and neck squamous cell carcinoma (HNSCC), a prevalent cancer type in India driven by tobacco chewing, areca nut (supari) consumption, alcohol, and late diagnoses, forms the focus of this analysis. These cancers account for a significant portion of India's oncology burden, with projections indicating over 1.5 million new cancer cases annually by 2026 according to National Cancer Registry Programme (NCRP) data and GLOBOCAN estimates. The study underscores how high drug costs exacerbate out-of-pocket expenditures, pushing families into financial distress.
Key Findings from the TMC-ACTREC Affordability Analysis
Lead author Dr. Arjun Singh, a surgical oncologist at TMC, and senior author Dr. Pankaj Chaturvedi, Director of ACTREC, compared the costs of key drugs relative to average monthly incomes. Immunotherapies like pembrolizumab (brand name Keytruda) and nivolumab emerged as the most burdensome. In India, a standard six-month course of pembrolizumab costs approximately Rs 60-65 lakh, equating to nearly 80 times the average monthly income of around Rs 25,000. Nivolumab for the same duration exceeds 20 times that figure.
This disparity highlights a critical imbalance: the funds required for one pembrolizumab patient could cover treatment for 18-22 patients using lower-cost targeted therapies such as gefitinib or erlotinib, oral tyrosine kinase inhibitors (TKIs) commonly used in HNSCC. While immunotherapies offer incremental survival benefits—often just 2-3 months in trials—their prices do not align with the value provided, especially when most Indian patients self-fund care.
Breaking Down the Costs: Immunotherapies vs. Targeted Therapies
Pembrolizumab, a programmed death-1 (PD-1) inhibitor, works by unleashing the immune system against cancer cells. Administered intravenously every three weeks, its high production complexity drives costs. In India, monthly pricing hovers at Rs 10.1 lakh per patient, totaling over Rs 1.2 crore annually. Globally, six months of treatment represents 591% of monthly income in the US, 903% in the UK, and even higher in South Asia: 4,311% in Pakistan and 3,133% in Bangladesh.
- Pembrolizumab (Keytruda): Rs 60-65 lakh for 6 months (~80x avg. monthly income India).
- Nivolumab (Opdivo): >20x avg. monthly income for 6 months.
- Gefitinib (TKI generic): Rs 5,000/month, vastly more accessible.
- Erlotinib/Cetuximab: Lower costs enable wider use despite varying efficacy.
Targeted therapies, which block specific cancer cell pathways, provide viable alternatives at fractions of the cost, allowing resource allocation to more patients.
The Head and Neck Cancer Epidemic in India
India bears a disproportionate HNSCC load, with tobacco-areca-alcohol synergies fueling incidence. NCRP data projects cancer cases rising to 1.57 million by 2025, with HNSCC prominent among men. Late-stage presentations—over 70% at diagnosis—demand multimodal treatment: surgery, radiation, chemotherapy, and increasingly biologics. Yet, affordability barriers mean many forgo optimal care, leading to higher mortality.
Non-medical costs compound the crisis: 83% of patients face catastrophic expenses, with 75% traveling over 500 km for specialized care like at TMC. Rural-urban divides exacerbate access issues.
Global Pricing Disparities and Lessons for India
The study's seven-country analysis shows no nation deems immunotherapies truly affordable. High-income countries negotiate bulk deals or insurance coverage, but even there, burdens persist. In LMICs, out-of-pocket dominance amplifies poverty risks. India's context—limited universal coverage—demands localized solutions like generics and biosimilars.PIB Release
| Drug & Duration | India (% Monthly Income) | US | UK |
|---|---|---|---|
| Pembrolizumab 6 mo. | ~8,000% | 591% | 903% |
| Nivolumab 6 mo. | >2,000% | High | High |
Patient Impacts: Financial Catastrophe and Equity Gaps
Cancer impoverishes households: medicines comprise 60%+ of out-of-pocket spend. TMC patients often sell assets or borrow, with newer drugs accelerating debt. Equity suffers—affluent access immunotherapies, while masses rely on palliation. Dr. Singh notes: “Immunotherapy is out of reach for most families; a 6-month course exceeds years of income.”
Government and Institutional Responses to the Crisis
India's Ayushman Bharat scheme covers 500 million, including cancer care up to Rs 5 lakh. Budget 2025-26 exempted customs duties on 17-36 cancer drugs, prompting NPPA price revisions. TMC's National Cancer Grid (NCG) pooled procurement slashed costs 82%, saving US$116 million.
- NPPA ceiling prices on 131 anti-cancer drugs.
- Production Linked Incentive (PLI) for generics/biosimilars.
- Customs duty waivers passed to patients via MRP cuts.
TMC expands satellite centers for doorstep care.TMC Affordable Care Project
Expert Perspectives and Calls for Reform
Dr. Chaturvedi emphasizes: “Prevention, early detection, and accessible treatment reduce deaths; expensive drugs alone won't suffice.” Recommendations include evidence-based use, biosimilar promotion, regulatory pricing, and tobacco control. Researchers urge context-specific trials for low-dose regimens.
Role of Research Institutions like TMC and ACTREC
As Homi Bhabha National Institute (HBNI) affiliates, TMC and ACTREC drive oncology education and research. Studies like this inform policy, training 1,000+ fellows yearly. Aspiring researchers can explore opportunities in cancer pharmacology via higher-ed-jobs/research-jobs or India-specific academic positions.
Future Directions: Biosimilars, Innovation, and Policy
Biosimilars could halve costs; PLI boosts local production. Precision medicine tailors therapy, reducing waste. Prevention via HPV vaccines, screening, and lifestyle shifts offers long-term relief. By 2030, NCRP targets doubled infrastructure.
In conclusion, the TMC-ACTREC study galvanizes action against the cancer drug affordability crisis. While progress via policy and innovation heartens, equitable access demands sustained commitment. For career advice in oncology research, visit higher-ed-career-advice; browse rate-my-professor for insights; explore higher-ed-jobs and university-jobs.
